Searching journal content for androgen receptor (as phrase) in full text.

Displaying results 1-10 of 356
For checked items
  1. Research:
    • Zhu Wang,
    • Dinglan Wu,
    • Chi-Fai Ng,
    • Jeremy Yuen-Chun Teoh,
    • Shan Yu,
    • Yuliang Wang,
    • and Franky Leung Chan
    Nuclear receptor profiling in prostatospheroids and castration-resistant prostate cancer Endocr Relat Cancer ERC-17-0280, doi:10.1530/ERC-17-0280 first published on 17 October 2017
    ...Sciences, Faculty of Medicine, 16 The Chinese University of Hong Kong, Shatin, New Territories, Hong Kong, China; phone: 17 +86 (852) 39436841; fax: +86 (852) 26035123; email: [email protected]; 18 [email protected] 19 Abbreviations 20 NR: nuclear receptor; AR: androgen receptor; PCSCs ~~~
  2. Review:
    • Gido Snaterse,
    • Jenny A Visser,
    • Wiebke Arlt,
    • and Johannes Hofland
    Circulating steroid hormone variations throughout different stages of prostate cancer Endocr Relat Cancer 24 (11) R403-R420, doi:10.1530/ERC-17-0155 first published on 18 September 2017
    .... The androgen receptor is the primary driver of tumor cell proliferation and is activated by the androgens testosterone and 5-dihydrotestosterone. Inhibition of this pathway through medical or surgical castration improves survival in the majority of advanced prostate cancer patients. However, conversion ~~~
  3. Review:
    • Gianmarco Leone,
    • Marcello Tucci,
    • Consuelo Buttigliero,
    • Clizia Zichi,
    • Daniele Pignataro,
    • Paolo Bironzo,
    • Francesca Vignani,
    • Giorgio Scagliotti,
    • and Massimo Di Maio
    Anti-androgen withdrawal syndrome (AAWS) in the treatment of patients with prostate cancer Endocr Relat Cancer ERC-17-0355, doi:10.1530/ERC-17-0355 first published on 28 September 2017
    ...-generation hormonal therapies. Several in vitro studies suggest that androgen receptor 23 gain-of-function mutations are involved in this syndrome, shifting the antiandrogen activity from 24 antagonist to agonist. Several different drug-specific point mutations have been reported. The 25 association of the withdrawal ~~~
  4. Commentary:
    • Giorgio Secreto,
    • Paola Muti,
    • Milena Sant,
    • Elisabetta Meneghini,
    • and Vittorio Krogh
    Medical ovariectomy in menopausal breast cancer patients with high testosterone levels: a further step toward tailored therapy Endocr Relat Cancer 24 (11) C21-C29, doi:10.1530/ERC-17-0251 first published on 16 August 2017
    ...production may account for renewed excessive estrogen formation and increased risks of late relapse. In the 50% of patients who do not benefit with anti-estrogens, the effect of therapy is limited by de novo or acquired resistance to treatment. Androgen receptor and epidermal growth factor receptor ~~~
  5. Thematic Review:
    • Koen M A Dreijerink,
    • H T Marc Timmers,
    • and Myles Brown
    Twenty years of menin: emerging opportunities for restoration of transcriptional regulation in MEN1 Endocr Relat Cancer 24 (10) T135-T145, doi:10.1530/ERC-17-0281 first published on 15 August 2017
    ...receptor (RXR), the peroxisome proliferator-activated receptors (PPAR) alpha and gamma, the liver X receptor (LXR) alpha and the androgen receptor (AR) (Dreijerink etal. 2006, 2009a, Cheng etal. 2011, 2015, Malik etal. 2015). The clinical relevance of the meninNR interaction was investigated ~~~
  6. Review:
    • Catherine Zabkiewicz,
    • Jeyna Resaul,
    • Rachel Hargest,
    • Wen Guo Jiang,
    • and Lin Ye
    Bone morphogenetic proteins, breast cancer, and bone metastases: striking the right balance Endocr Relat Cancer 24 (10) R349-R366, doi:10.1530/ERC-17-0139 first published on 21 July 2017
    ...). This highlights the important influence of other signalling pathways and the canonical or noncanonical BMP signalling pathways, and may be one of the reasons for the varied and sometimes contradictory study outcomes regarding BMPs in breast cancer. BMPs and the androgen receptor More recently androgen receptor ~~~
    OPEN ACCESS ARTICLE
  7. Review:
    • Melissa Gamat and
    • Douglas G McNeel
    Androgen deprivation and immunotherapy for the treatment of prostate cancer Endocr Relat Cancer ERC-17-0145, doi:10.1530/ERC-17-0145 first published on 16 August 2017
    ...therapy, AR androgen receptor, CRPC castration resistant 22 prostate cancer, DHT dihydrotestosterone, LHRH Luteinizing Hormone Releasing Hormone, PSA prostate 23 specific antigen, sip-T sipuleucel T 24 25 26 27 28 Page 1 of 32 Accepted Preprint first posted on 16 August 2017 as Manuscript ERC-17 ~~~
  8. Thematic Review:
    • Shivangi Agarwal and
    • Dileep Varma
    Targeting mitotic pathways for endocrine-related cancer therapeutics Endocr Relat Cancer 24 (9) T65-T82, doi:10.1530/ERC-17-0080 first published on 14 June 2017
    ...androgen receptor mediated therapeutic target for prostate cancer. Endocrine-Related Cancer 16 325–332. (doi:10.1677/-08-0205) Dai J & Higgins JM 2005 Haspin: a mitotic histone kinase required for metaphase chromosome alignment. Cell Cycle 4 665–668. (doi:10.4161/cc.4.5.1683) DeBonis S, Skoufias DA, ~~~
  9. Review:
    • Takuma Uo,
    • Stephen R Plymate,
    • and Cynthia C Sprenger
    Allosteric alterations in the androgen receptor and activity in prostate cancer Endocr Relat Cancer 24 (9) R335-R348, doi:10.1530/ERC-17-0108
    ...number of genes. This concept holds true for the androgen receptor, which displays a diversity of inclusion/exclusion events in its structural motifs as a mechanism of resistance to the most forefront anti-androgen therapies. More than 20 androgen receptor variants that lack various portions of ligand ~~~
  10. Thematic Review:
    • Angela Ogden,
    • Padmashree C G Rida,
    • and Ritu Aneja
    Centrosome amplification: a suspect in breast cancer and racial disparities Endocr Relat Cancer 24 (9) T47-T64, doi:10.1530/ERC-17-0072 first published on 17 May 2017
    ...androgen receptor subtype (Lindner et al. 2013). Thus, it is reasonable to conjecture that the basal-like 1 subtype evinces greater CA than the luminal androgen receptor subtypes, an interesting avenue for future research. Conclusions In summary, CA appears to be a correlate of aggressive disease fe ~~~
For checked items

Search Results

Next 10 » New Search

Modify Results

Citation format:
Results / page:
Results order:

This search

  • Alert me when new articles matching this search are published
  • Download all citations on this page to my citation manager

New Articles: issue in progress

  1. November 2017, 24 (11)
  1. Current Issue
  1. Alert me to new issues of Endocrine-Related Cancer

Most